Loading…

Surgical treatment outcome of primary aldosteronism assessed using new modified diagnostic tests

Purpose Primary aldosteronism (PA) is the most frequent type of endocrine hypertension. In our previous studies, we introduced two modified diagnostic tests for PA, the post-dexamethasone saline infusion test (DSIT) and the overnight dexamethasone, captopril, and valsartan test (DCVT). In this study...

Full description

Saved in:
Bibliographic Details
Published in:Hormones (Athens, Greece) Greece), 2021-06, Vol.20 (2), p.359-368
Main Authors: Alexandraki, Krystallenia I., Markou, Athina, Papanastasiou, Labrini, Tyfoxylou, Ernestini, Kapsali, Chara, Gravvanis, Christos, Katsiveli, Pinelopi, Kaltsas, Gregory A., Zografos, George N., Chrousos, George P., Piaditis, George
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c347t-f6eb14c4c6d1090fac11f564e02329eecc8d31ca4002d8bfe2001b7a8085f06e3
cites cdi_FETCH-LOGICAL-c347t-f6eb14c4c6d1090fac11f564e02329eecc8d31ca4002d8bfe2001b7a8085f06e3
container_end_page 368
container_issue 2
container_start_page 359
container_title Hormones (Athens, Greece)
container_volume 20
creator Alexandraki, Krystallenia I.
Markou, Athina
Papanastasiou, Labrini
Tyfoxylou, Ernestini
Kapsali, Chara
Gravvanis, Christos
Katsiveli, Pinelopi
Kaltsas, Gregory A.
Zografos, George N.
Chrousos, George P.
Piaditis, George
description Purpose Primary aldosteronism (PA) is the most frequent type of endocrine hypertension. In our previous studies, we introduced two modified diagnostic tests for PA, the post-dexamethasone saline infusion test (DSIT) and the overnight dexamethasone, captopril, and valsartan test (DCVT). In this study, we aimed to validate both tests in respect to the biochemical and clinical response of a cohort of hypertensive patients in pre- and post-surgical setting. Methods We retrospectively studied 41 hypertensive patients (16 males), with a median (IQR, range) age of 50 (16, 35–74) years and positive histology for adrenal adenoma. Preoperatively, all patients had a single adenoma on CT and a diagnosis of PA with either DSIT or DCVT. The defined daily dose (DDD) of hypertensive drugs was assessed pre- and postoperatively. DSIT or DCVT and basal ARR were reassessed postoperatively. Results Two of the 41 patients failed to suppress aldosterone post-surgery, leading to a post-adrenalectomy biochemical cure rate of 95%, while blood pressure was improved in 36 patients, leading to a clinical cure rate of 88% as assessed by the DDD methodology. Conclusions The present study was a proof-of-concept process to validate two modified diagnostic tests for PA in clinical practice. These tests, used to diagnose a group of patients with PA, successfully assessed their biochemical cure post-adrenalectomy at rates similar to those reported in the literature.
doi_str_mv 10.1007/s42000-021-00280-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2504775892</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2504775892</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-f6eb14c4c6d1090fac11f564e02329eecc8d31ca4002d8bfe2001b7a8085f06e3</originalsourceid><addsrcrecordid>eNp9kE1PxCAQhonRuOvqH_BgOHqpDtAPejQbv5JNPKhnpHTYsGnLCm2M_150V48mJEOYd97hfQg5Z3DFAKrrmHMAyICzDIBLyOQBmfOCp0vF2SGZMwZ1JqCuZ-Qkxg1AWdSSHZOZEFVR1KKck7fnKayd0R0dA-qxx2GkfhqN75F6S7fB9Tp8Ut21Po4Y_OBiT3WMmE5Lp-iGNR3wg_a-ddalp9bp9ZC0ztAR4xhPyZHVXcSzfV2Q17vbl-VDtnq6f1zerDIj8mrMbIkNy01uyjZ9Gqw2jNmizBG44DWiMbIVzOg8JW1lYzFFZ02lJcjCQoliQS53vtvg36e0WfUuGuw6PaCfouIF5FVVyJonKd9JTfAxBrRqH1MxUN9k1Y6sSmTVD1kl09DF3n9qemz_Rn5RJoHYCWJqDWsMauOnMKTM_9l-AY7Rhd0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2504775892</pqid></control><display><type>article</type><title>Surgical treatment outcome of primary aldosteronism assessed using new modified diagnostic tests</title><source>Springer</source><creator>Alexandraki, Krystallenia I. ; Markou, Athina ; Papanastasiou, Labrini ; Tyfoxylou, Ernestini ; Kapsali, Chara ; Gravvanis, Christos ; Katsiveli, Pinelopi ; Kaltsas, Gregory A. ; Zografos, George N. ; Chrousos, George P. ; Piaditis, George</creator><creatorcontrib>Alexandraki, Krystallenia I. ; Markou, Athina ; Papanastasiou, Labrini ; Tyfoxylou, Ernestini ; Kapsali, Chara ; Gravvanis, Christos ; Katsiveli, Pinelopi ; Kaltsas, Gregory A. ; Zografos, George N. ; Chrousos, George P. ; Piaditis, George</creatorcontrib><description>Purpose Primary aldosteronism (PA) is the most frequent type of endocrine hypertension. In our previous studies, we introduced two modified diagnostic tests for PA, the post-dexamethasone saline infusion test (DSIT) and the overnight dexamethasone, captopril, and valsartan test (DCVT). In this study, we aimed to validate both tests in respect to the biochemical and clinical response of a cohort of hypertensive patients in pre- and post-surgical setting. Methods We retrospectively studied 41 hypertensive patients (16 males), with a median (IQR, range) age of 50 (16, 35–74) years and positive histology for adrenal adenoma. Preoperatively, all patients had a single adenoma on CT and a diagnosis of PA with either DSIT or DCVT. The defined daily dose (DDD) of hypertensive drugs was assessed pre- and postoperatively. DSIT or DCVT and basal ARR were reassessed postoperatively. Results Two of the 41 patients failed to suppress aldosterone post-surgery, leading to a post-adrenalectomy biochemical cure rate of 95%, while blood pressure was improved in 36 patients, leading to a clinical cure rate of 88% as assessed by the DDD methodology. Conclusions The present study was a proof-of-concept process to validate two modified diagnostic tests for PA in clinical practice. These tests, used to diagnose a group of patients with PA, successfully assessed their biochemical cure post-adrenalectomy at rates similar to those reported in the literature.</description><identifier>ISSN: 1109-3099</identifier><identifier>EISSN: 2520-8721</identifier><identifier>DOI: 10.1007/s42000-021-00280-8</identifier><identifier>PMID: 33755936</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adenoma ; Captopril ; Dexamethasone ; Diagnostic Tests, Routine ; Dichlorodiphenyldichloroethane ; Endocrinology ; Humans ; Hyperaldosteronism - diagnosis ; Hyperaldosteronism - surgery ; Hypertension - diagnosis ; Hypertension - drug therapy ; Medicine ; Medicine &amp; Public Health ; Metabolic Diseases ; Original Article ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Hormones (Athens, Greece), 2021-06, Vol.20 (2), p.359-368</ispartof><rights>Hellenic Endocrine Society 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-f6eb14c4c6d1090fac11f564e02329eecc8d31ca4002d8bfe2001b7a8085f06e3</citedby><cites>FETCH-LOGICAL-c347t-f6eb14c4c6d1090fac11f564e02329eecc8d31ca4002d8bfe2001b7a8085f06e3</cites><orcidid>0000-0002-5876-7883 ; 0000-0003-2398-6768</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33755936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alexandraki, Krystallenia I.</creatorcontrib><creatorcontrib>Markou, Athina</creatorcontrib><creatorcontrib>Papanastasiou, Labrini</creatorcontrib><creatorcontrib>Tyfoxylou, Ernestini</creatorcontrib><creatorcontrib>Kapsali, Chara</creatorcontrib><creatorcontrib>Gravvanis, Christos</creatorcontrib><creatorcontrib>Katsiveli, Pinelopi</creatorcontrib><creatorcontrib>Kaltsas, Gregory A.</creatorcontrib><creatorcontrib>Zografos, George N.</creatorcontrib><creatorcontrib>Chrousos, George P.</creatorcontrib><creatorcontrib>Piaditis, George</creatorcontrib><title>Surgical treatment outcome of primary aldosteronism assessed using new modified diagnostic tests</title><title>Hormones (Athens, Greece)</title><addtitle>Hormones</addtitle><addtitle>Hormones (Athens)</addtitle><description>Purpose Primary aldosteronism (PA) is the most frequent type of endocrine hypertension. In our previous studies, we introduced two modified diagnostic tests for PA, the post-dexamethasone saline infusion test (DSIT) and the overnight dexamethasone, captopril, and valsartan test (DCVT). In this study, we aimed to validate both tests in respect to the biochemical and clinical response of a cohort of hypertensive patients in pre- and post-surgical setting. Methods We retrospectively studied 41 hypertensive patients (16 males), with a median (IQR, range) age of 50 (16, 35–74) years and positive histology for adrenal adenoma. Preoperatively, all patients had a single adenoma on CT and a diagnosis of PA with either DSIT or DCVT. The defined daily dose (DDD) of hypertensive drugs was assessed pre- and postoperatively. DSIT or DCVT and basal ARR were reassessed postoperatively. Results Two of the 41 patients failed to suppress aldosterone post-surgery, leading to a post-adrenalectomy biochemical cure rate of 95%, while blood pressure was improved in 36 patients, leading to a clinical cure rate of 88% as assessed by the DDD methodology. Conclusions The present study was a proof-of-concept process to validate two modified diagnostic tests for PA in clinical practice. These tests, used to diagnose a group of patients with PA, successfully assessed their biochemical cure post-adrenalectomy at rates similar to those reported in the literature.</description><subject>Adenoma</subject><subject>Captopril</subject><subject>Dexamethasone</subject><subject>Diagnostic Tests, Routine</subject><subject>Dichlorodiphenyldichloroethane</subject><subject>Endocrinology</subject><subject>Humans</subject><subject>Hyperaldosteronism - diagnosis</subject><subject>Hyperaldosteronism - surgery</subject><subject>Hypertension - diagnosis</subject><subject>Hypertension - drug therapy</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metabolic Diseases</subject><subject>Original Article</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>1109-3099</issn><issn>2520-8721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kE1PxCAQhonRuOvqH_BgOHqpDtAPejQbv5JNPKhnpHTYsGnLCm2M_150V48mJEOYd97hfQg5Z3DFAKrrmHMAyICzDIBLyOQBmfOCp0vF2SGZMwZ1JqCuZ-Qkxg1AWdSSHZOZEFVR1KKck7fnKayd0R0dA-qxx2GkfhqN75F6S7fB9Tp8Ut21Po4Y_OBiT3WMmE5Lp-iGNR3wg_a-ddalp9bp9ZC0ztAR4xhPyZHVXcSzfV2Q17vbl-VDtnq6f1zerDIj8mrMbIkNy01uyjZ9Gqw2jNmizBG44DWiMbIVzOg8JW1lYzFFZ02lJcjCQoliQS53vtvg36e0WfUuGuw6PaCfouIF5FVVyJonKd9JTfAxBrRqH1MxUN9k1Y6sSmTVD1kl09DF3n9qemz_Rn5RJoHYCWJqDWsMauOnMKTM_9l-AY7Rhd0</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Alexandraki, Krystallenia I.</creator><creator>Markou, Athina</creator><creator>Papanastasiou, Labrini</creator><creator>Tyfoxylou, Ernestini</creator><creator>Kapsali, Chara</creator><creator>Gravvanis, Christos</creator><creator>Katsiveli, Pinelopi</creator><creator>Kaltsas, Gregory A.</creator><creator>Zografos, George N.</creator><creator>Chrousos, George P.</creator><creator>Piaditis, George</creator><general>Springer International Publishing</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5876-7883</orcidid><orcidid>https://orcid.org/0000-0003-2398-6768</orcidid></search><sort><creationdate>202106</creationdate><title>Surgical treatment outcome of primary aldosteronism assessed using new modified diagnostic tests</title><author>Alexandraki, Krystallenia I. ; Markou, Athina ; Papanastasiou, Labrini ; Tyfoxylou, Ernestini ; Kapsali, Chara ; Gravvanis, Christos ; Katsiveli, Pinelopi ; Kaltsas, Gregory A. ; Zografos, George N. ; Chrousos, George P. ; Piaditis, George</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-f6eb14c4c6d1090fac11f564e02329eecc8d31ca4002d8bfe2001b7a8085f06e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenoma</topic><topic>Captopril</topic><topic>Dexamethasone</topic><topic>Diagnostic Tests, Routine</topic><topic>Dichlorodiphenyldichloroethane</topic><topic>Endocrinology</topic><topic>Humans</topic><topic>Hyperaldosteronism - diagnosis</topic><topic>Hyperaldosteronism - surgery</topic><topic>Hypertension - diagnosis</topic><topic>Hypertension - drug therapy</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metabolic Diseases</topic><topic>Original Article</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alexandraki, Krystallenia I.</creatorcontrib><creatorcontrib>Markou, Athina</creatorcontrib><creatorcontrib>Papanastasiou, Labrini</creatorcontrib><creatorcontrib>Tyfoxylou, Ernestini</creatorcontrib><creatorcontrib>Kapsali, Chara</creatorcontrib><creatorcontrib>Gravvanis, Christos</creatorcontrib><creatorcontrib>Katsiveli, Pinelopi</creatorcontrib><creatorcontrib>Kaltsas, Gregory A.</creatorcontrib><creatorcontrib>Zografos, George N.</creatorcontrib><creatorcontrib>Chrousos, George P.</creatorcontrib><creatorcontrib>Piaditis, George</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hormones (Athens, Greece)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alexandraki, Krystallenia I.</au><au>Markou, Athina</au><au>Papanastasiou, Labrini</au><au>Tyfoxylou, Ernestini</au><au>Kapsali, Chara</au><au>Gravvanis, Christos</au><au>Katsiveli, Pinelopi</au><au>Kaltsas, Gregory A.</au><au>Zografos, George N.</au><au>Chrousos, George P.</au><au>Piaditis, George</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Surgical treatment outcome of primary aldosteronism assessed using new modified diagnostic tests</atitle><jtitle>Hormones (Athens, Greece)</jtitle><stitle>Hormones</stitle><addtitle>Hormones (Athens)</addtitle><date>2021-06</date><risdate>2021</risdate><volume>20</volume><issue>2</issue><spage>359</spage><epage>368</epage><pages>359-368</pages><issn>1109-3099</issn><eissn>2520-8721</eissn><abstract>Purpose Primary aldosteronism (PA) is the most frequent type of endocrine hypertension. In our previous studies, we introduced two modified diagnostic tests for PA, the post-dexamethasone saline infusion test (DSIT) and the overnight dexamethasone, captopril, and valsartan test (DCVT). In this study, we aimed to validate both tests in respect to the biochemical and clinical response of a cohort of hypertensive patients in pre- and post-surgical setting. Methods We retrospectively studied 41 hypertensive patients (16 males), with a median (IQR, range) age of 50 (16, 35–74) years and positive histology for adrenal adenoma. Preoperatively, all patients had a single adenoma on CT and a diagnosis of PA with either DSIT or DCVT. The defined daily dose (DDD) of hypertensive drugs was assessed pre- and postoperatively. DSIT or DCVT and basal ARR were reassessed postoperatively. Results Two of the 41 patients failed to suppress aldosterone post-surgery, leading to a post-adrenalectomy biochemical cure rate of 95%, while blood pressure was improved in 36 patients, leading to a clinical cure rate of 88% as assessed by the DDD methodology. Conclusions The present study was a proof-of-concept process to validate two modified diagnostic tests for PA in clinical practice. These tests, used to diagnose a group of patients with PA, successfully assessed their biochemical cure post-adrenalectomy at rates similar to those reported in the literature.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>33755936</pmid><doi>10.1007/s42000-021-00280-8</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5876-7883</orcidid><orcidid>https://orcid.org/0000-0003-2398-6768</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1109-3099
ispartof Hormones (Athens, Greece), 2021-06, Vol.20 (2), p.359-368
issn 1109-3099
2520-8721
language eng
recordid cdi_proquest_miscellaneous_2504775892
source Springer
subjects Adenoma
Captopril
Dexamethasone
Diagnostic Tests, Routine
Dichlorodiphenyldichloroethane
Endocrinology
Humans
Hyperaldosteronism - diagnosis
Hyperaldosteronism - surgery
Hypertension - diagnosis
Hypertension - drug therapy
Medicine
Medicine & Public Health
Metabolic Diseases
Original Article
Retrospective Studies
Treatment Outcome
title Surgical treatment outcome of primary aldosteronism assessed using new modified diagnostic tests
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-06T18%3A58%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Surgical%20treatment%20outcome%20of%20primary%20aldosteronism%20assessed%20using%20new%20modified%20diagnostic%20tests&rft.jtitle=Hormones%20(Athens,%20Greece)&rft.au=Alexandraki,%20Krystallenia%20I.&rft.date=2021-06&rft.volume=20&rft.issue=2&rft.spage=359&rft.epage=368&rft.pages=359-368&rft.issn=1109-3099&rft.eissn=2520-8721&rft_id=info:doi/10.1007/s42000-021-00280-8&rft_dat=%3Cproquest_cross%3E2504775892%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c347t-f6eb14c4c6d1090fac11f564e02329eecc8d31ca4002d8bfe2001b7a8085f06e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2504775892&rft_id=info:pmid/33755936&rfr_iscdi=true